Drug Profile
LU 302872
Alternative Names: BSF-302872; LU-302872Latest Information Update: 12 Feb 2013
Price :
$50
*
At a glance
- Originator Abbott GmbH & Co. KG
- Class Propionic acids; Pyrimidines; Small molecules
- Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 31 Dec 2012 Discontinued - Preclinical for Benign prostatic hyperplasia in Germany (PO) before 2012
- 09 Dec 2003 No development reported - Preclinical for Benign prostatic hyperplasia in Germany (PO)
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories